Article
p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Blood cancer journal - 10 Jun 2016
Lee H J, Gallardo M, Ma H, Zhang X, Larsson C A, Mejia A, Hornbaker M J, Qi Y, Su X, Pageon L R, Quintas-Cardama A, Post S M
Abstract excerpt
Deletion of the short-arm of chromosome 17 (17p-) is one of the most critical genetic alterations used in chronic lymphocytic leukemia (CLL) risk stratification. The tumor suppressor TP53 maps to this region, and its loss or mutation accelerates CLL progression, hampers response to chemotherapy and shortens survival. Although florescent in situ hybridization analyses for 17p deletions are routinely performed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.